Spots Global Cancer Trial Database for A Study of E7070 in Patients With Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of E7070 in Patients With Gastric Cancer
Official Title: Non-Randomized, Open, Uncontrolled, Dose Comparison Study of E7070 in Patients With Gastric Cancer
Study ID: NCT00165594
Conditions
Interventions
Study Description
Brief Summary: Phase I study: To investigate primary objective (maximal tolerated dose and dose-limiting toxicity) and secondary objectives (pharmacokinetics, safety, estimation of a recommended dose, and anti-tumor effect by evaluable case) of E7070 in patients with gastric cancer who are extensive or intermediate metabolizer type (EM/IM) to CYP2C9 and CYP2C9 by intravenously administering once every 3 weeks. Phase IIa study: To investigate primary objective (response rate for efficacy assessment) and secondary objectives (frequency and severity of adverse drug reactions, and pharmacokinetics) of E7070 in patient with gastric cancer who are EM/IM type by intravenously administering once every 3 weeks.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Kashiwa, Chiba-prefecture, Japan
, Sagamihara-shi, Kanagawa, Japan
, Takatsuki-shi, Osaka, Japan
, Sunto-gun, Shizuoka-prefecture, Japan
, Chuo-ku, Tokyo, Japan
Contact Details
Name: Tatsuo Watanabe
Affiliation: Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
